These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 26743887)
1. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Gallagher H; Suckling RJ Diabetes Obes Metab; 2016 Jul; 18(7):641-7. PubMed ID: 26743887 [TBL] [Abstract][Full Text] [Related]
2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
4. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?]. Luño J; Valderrábano F An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851 [No Abstract] [Full Text] [Related]
5. Diabetic nephropathy: changing concepts of pathogenesis and treatment. Bell DS Am J Med Sci; 1991 Mar; 301(3):195-200. PubMed ID: 2000893 [TBL] [Abstract][Full Text] [Related]
6. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
7. The renin-angiotensin system and diabetic nephropathy. Gurley SB; Coffman TM Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors. Crook ED; Preddie DC Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155 [TBL] [Abstract][Full Text] [Related]
9. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II). Jacobsen PK J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484 [TBL] [Abstract][Full Text] [Related]
10. The importance of diabetic nephropathy in current nephrological practice. Locatelli F; Canaud B; Eckardt KU; Stenvinkel P; Wanner C; Zoccali C Nephrol Dial Transplant; 2003 Sep; 18(9):1716-25. PubMed ID: 12937216 [TBL] [Abstract][Full Text] [Related]
11. [Diabetic nephropathy: natural history and therapeutic interventions]. Scheen AJ Rev Med Liege; 1993 Dec; 48(12):645-58. PubMed ID: 8310199 [No Abstract] [Full Text] [Related]
12. The role of angiotensin receptor blockers in diabetic nephropathy. Sharma AM; Weir MR Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421 [TBL] [Abstract][Full Text] [Related]
15. Management of nephropathy in patients with type 2 diabetes. Critchley JA; Zhao HL; Tomlinson B; Leung W; Thomas GN; Chan JC; Cockram CS Chin Med J (Engl); 2002 Jan; 115(1):129-35. PubMed ID: 11930647 [TBL] [Abstract][Full Text] [Related]
16. [Prevention and remission of diabetic nephropathy]. Sugimoto T; Nakamura Y; Makino H Nihon Rinsho; 2003 Jul; 61(7):1167-71. PubMed ID: 12877079 [TBL] [Abstract][Full Text] [Related]
17. Current concepts in the management of diabetic nephropathy. Waanders F; Visser FW; Gans RO Neth J Med; 2013 Nov; 71(9):448-58. PubMed ID: 24218418 [TBL] [Abstract][Full Text] [Related]
18. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]